In a study carried out by Kratochwil et al. [2], dosimetric estimations for 14 prostate cancer patients injected with [225Ac]Ac-PSMA-617 were performed based on TACs derived from [177Lu]Lu-PSMA-617 scans that were adjusted for the physical half-life of 225Ac. Here, FOLH1 is linked to prostate cancer.